IRIS
MANNI, ALESSIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.834
AS - Asia 756
EU - Europa 687
SA - Sud America 147
Continente sconosciuto - Info sul continente non disponibili 130
AF - Africa 73
OC - Oceania 2
Totale 3.629
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.755
SG - Singapore 318
IT - Italia 214
CN - Cina 141
RU - Federazione Russa 117
BR - Brasile 113
HK - Hong Kong 85
SE - Svezia 77
VN - Vietnam 76
DE - Germania 60
GB - Regno Unito 57
FR - Francia 44
CA - Canada 43
CI - Costa d'Avorio 40
FI - Finlandia 33
BD - Bangladesh 30
IN - India 22
ID - Indonesia 17
BE - Belgio 14
ZA - Sudafrica 14
JP - Giappone 12
MX - Messico 12
NL - Olanda 12
ES - Italia 11
IQ - Iraq 11
TR - Turchia 11
AR - Argentina 10
PL - Polonia 10
CO - Colombia 8
LT - Lituania 8
UA - Ucraina 8
TN - Tunisia 6
EC - Ecuador 5
PK - Pakistan 5
SA - Arabia Saudita 5
SV - El Salvador 5
JM - Giamaica 4
PH - Filippine 4
VE - Venezuela 4
AL - Albania 3
CR - Costa Rica 3
HU - Ungheria 3
JO - Giordania 3
KE - Kenya 3
NI - Nicaragua 3
OM - Oman 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
AU - Australia 2
BB - Barbados 2
CL - Cile 2
CZ - Repubblica Ceca 2
EU - Europa 2
GT - Guatemala 2
LK - Sri Lanka 2
PE - Perù 2
PR - Porto Rico 2
RO - Romania 2
AO - Angola 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BG - Bulgaria 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
GH - Ghana 1
GM - Gambi 1
GR - Grecia 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
MZ - Mozambico 1
NP - Nepal 1
PA - Panama 1
PY - Paraguay 1
SN - Senegal 1
SX - ???statistics.table.value.countryCode.SX??? 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 3.502
Salva come PNG Salva come JPEG
Città #
Ashburn 253
Singapore 186
San Jose 166
Fairfield 145
Chandler 115
Woodbridge 109
Hong Kong 85
Nyköping 61
Houston 58
Seattle 58
Council Bluffs 56
Beijing 54
Cambridge 46
Abidjan 40
Los Angeles 38
Milan 31
Wilmington 31
Ann Arbor 29
Helsinki 27
New York 27
Ho Chi Minh City 25
Munich 23
Bari 21
Lauterbourg 21
Brooklyn 19
Dallas 18
Santa Clara 18
Lawrence 16
Toronto 16
Moscow 15
Roxbury 15
São Paulo 15
Brussels 14
London 14
Rome 14
Chicago 13
Frankfurt am Main 13
Jakarta 13
Nuremberg 13
Boardman 11
Des Moines 11
Phoenix 11
Tokyo 11
Columbus 10
Jacksonville 10
Warsaw 10
Amsterdam 9
Atlanta 9
Hanoi 9
Johannesburg 9
Orem 9
Poplar 9
Bisceglie 8
Cagliari 8
Denver 8
Inglewood 8
Montreal 8
Buffalo 7
Falkenstein 7
Princeton 7
Baghdad 6
Dong Ket 6
Paris 6
San Francisco 6
Shenyang 6
Bologna 5
Chennai 5
Fano 5
Gravina in Puglia 5
Nanjing 5
Rio de Janeiro 5
Shanghai 5
Ankara 4
Da Nang 4
Dhaka 4
Guangzhou 4
Manchester 4
Mexico City 4
Naples 4
New Delhi 4
North Bergen 4
Norwalk 4
San Diego 4
San Salvador 4
Amman 3
Belo Horizonte 3
Boston 3
Brasília 3
Carrboro 3
Dearborn 3
Grottaglie 3
Haiphong 3
Lviv 3
Managua 3
Miami 3
Muscat 3
Nairobi 3
Palermo 3
Philadelphia 3
Querétaro 3
Totale 2.281
Salva come PNG Salva come JPEG
Nome #
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 242
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 193
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 188
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 180
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 178
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 174
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 167
Multiple Sclerosis Progression and Relapse Activity in Children 149
Development and validation of the ID-EC - The ITALIAN version of the identify chronic migraine 139
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis 134
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 134
Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group 134
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 127
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 125
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 124
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 124
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 120
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 116
Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study 112
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 111
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 104
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review 103
Dancing With Parkinson's Disease: The SI-ROBOTICS Study Protocol 97
Risk of Getting COVID-19 in People With Multiple Sclerosis 82
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 77
Neutralizing Antibodies and Multiple Sclerosis in the Era of Disease Modifying Treatments 66
The role of serum neurofilament light chain in an adult cohort of patients with acquired demyelinating syndromes of the central nervous system (P2-4.006) 49
A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study 43
Serum neurofilament light chain in a cohort of multiple sclerosis, MOG-antibody diseases and neuromyelitis optica spectrum disorders patients 37
Totale 3.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.452
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022130 0 0 0 5 8 20 5 9 10 12 27 34
2022/2023276 36 46 18 19 33 30 9 34 33 1 8 9
2023/2024110 18 17 5 15 14 15 3 6 0 7 0 10
2024/2025615 36 4 46 31 31 55 94 66 11 29 66 146
2025/20261.514 213 58 104 158 200 90 138 50 195 161 65 82
2026/2027317 72 51 60 134 0 0 0 0 0 0 0 0
Totale 3.629